Clinical Trial Update: Ranolazine for the Prevention of Atrial Fibrillation After Electrical Cardioversion [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating ranolazine to prevent atrial fibrillation after electrical cardioversion was terminated, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Ranolazine (ranolazine)

Snippet

Sponsor: University of Oklahoma | Conditions: Atrial Fibrillation | Phase 3 | Status: TERMINATED | Results posted: 2017-04-27